ADC Therapeutics SA Files 2024 Proxy Statement
Ticker: ADCT · Form: DEF 14A · Filed: Sep 23, 2024 · CIK: 1771910
| Field | Detail |
|---|---|
| Company | Adc Therapeutics SA (ADCT) |
| Form Type | DEF 14A |
| Filed Date | Sep 23, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 19 min |
| Key Dollar Amounts | $16,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, governance, shareholder-meeting
TL;DR
ADC Therapeutics SA filed its proxy statement for the Nov 11 meeting. Vote your shares!
AI Summary
ADC Therapeutics SA filed a definitive proxy statement (DEF 14A) on September 23, 2024, for its annual general meeting. The filing concerns the company's governance and shareholder matters, with the fiscal year ending December 31, 2024. The meeting is scheduled for November 11, 2024.
Why It Matters
This filing provides shareholders with crucial information regarding company leadership, voting matters, and executive compensation, enabling informed participation in corporate governance.
Risk Assessment
Risk Level: low — This is a routine regulatory filing (DEF 14A) and does not contain new material financial or operational information.
Key Numbers
- 20241111 — Meeting Date (Shareholders will vote on company matters on this date.)
- 1231 — Fiscal Year End (The company's financial reporting period.)
Key Players & Entities
- ADC Therapeutics SA (company) — Registrant
- 0000950103-24-013848 (filing_id) — Accession Number
- 20240923 (date) — Filing Date
- 20241111 (date) — Meeting Date
FAQ
What type of filing is this?
This is a Definitive Proxy Statement (DEF 14A) filed by ADC Therapeutics SA.
When was this filing submitted?
The filing was submitted on September 23, 2024.
What is the purpose of a DEF 14A filing?
A DEF 14A filing is a proxy statement filed by a company to solicit shareholder votes for an upcoming meeting.
When is the Extraordinary General Meeting of Shareholders scheduled?
The Extraordinary General Meeting of Shareholders is scheduled for November 11, 2024.
What is ADC Therapeutics SA's fiscal year end?
ADC Therapeutics SA's fiscal year ends on December 31.
Filing Stats: 4,810 words · 19 min read · ~16 pages · Grade level 13.6 · Accepted 2024-09-23 16:35:12
Key Financial Figures
- $16,000 — sist in the solicitation of proxies for $16,000. If you choose to access the proxy mat
Filing Documents
- dp218056_def14a.htm (DEF 14A) — 114KB
- image_001.jpg (GRAPHIC) — 4KB
- image_002.jpg (GRAPHIC) — 194KB
- image_003.jpg (GRAPHIC) — 200KB
- image_004.jpg (GRAPHIC) — 141KB
- image_005.jpg (GRAPHIC) — 386KB
- 0000950103-24-013848.txt ( ) — 1389KB
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 13 OTHER MATTERS 15 ADC Therapeutics SA Biopôle, Route de la Corniche 3B 1066 Epalinges Switzerland PROXY STATEMENT EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS Date and Time: November 11, 2024 at 10:00 AM EST / 4:00 PM CET Location: Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland This proxy statement (this “Proxy Statement”) and Notice of Extraordinary General Meeting of Shareholders are being provided to you in connection with the solicitation of proxies by our board of directors for use at our extraordinary general meeting of shareholders (the “Special Meeting”) to be held on November 11, 2024 at 10:00 AM EST / 4:00 PM CET at the Company’s headquarters located at Biopôle, Route de la Corniche 3B, 1066 Epalinges, Switzerland. Shareholders of record at the close of business on September 20, 2024 are invited to attend the Special Meeting and are entitled to vote on the proposals described in this Proxy Statement. On or about September 23, 2024, we made available this Proxy Statement and the attached Notice of Extraordinary General Meeting of Shareholders to all shareholders entitled to vote at the Special Meeting and we began sending the Notice Regarding the Availability of Proxy Materials to all shareholders entitled to vote at the Special Meeting. IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE EXTRAORDINARY MEETING OF SHAREHOLDERS TO BE HELD ON NOVEMBER 11, 2024 This Proxy Statement is not a form for voting and presents only an overview of the proxy materials, which contain important information. You are encouraged to access and view the complete proxy materials before voting. This Proxy Statement and the proxy materials are available for viewing, printing and downloading at ir.adctherapeutics.com/sec-filings/annual-reports-and-proxies/default.aspx . Additionally, you can find a copy of this P